Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ole Isacson, Dr.Med.Sci, M.B.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, Platt FM. Correction to: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2020 Jan 15; 15(1):6. PMID: 31937358.
    Citations:    
  2. Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, Platt FM. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2019 11 08; 14(1):40. PMID: 31703585.
    Citations:    
  3. Isacson O, Brekk OR, Hallett PJ. Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease. Front Neurol. 2019; 10:1053. PMID: 31649605.
    Citations:    
  4. Korecka JA, Thomas R, Christensen DP, Hinrich AJ, Ferrari EJ, Levy SA, Hastings ML, Hallett PJ, Isacson O. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts. Hum Mol Genet. 2019 10 01; 28(19):3232-3243. PMID: 31261377.
    Citations:    
  5. Menon V, Thomas R, Elgueta C, Horl M, Osborn T, Hallett PJ, Bartos M, Isacson O, Pruszak J. Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein-1 (CD71) as a Negative Selection Marker for Human Neuronal Cells. Stem Cells. 2019 10; 37(10):1293-1306. PMID: 31381839.
    Citations:    
  6. Hallett PJ, Engelender S, Isacson O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease. J Neuroinflammation. 2019 Jul 22; 16(1):153. PMID: 31331333.
    Citations:    
  7. Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, Moskites A, Atkinson E, Jodelka FM, Hinrich AJ, Hastings ML, Woolf CJ, Hallett PJ, Isacson O. Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation. Stem Cell Reports. 2019 01 08; 12(1):29-41. PMID: 30595548.
    Citations:    Fields:    
  8. Brekk OR, Moskites A, Isacson O, Hallett PJ. Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. Sci Rep. 2018 10 12; 8(1):15207. PMID: 30315256.
    Citations:    Fields:    
  9. Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. Neurobiol Dis. 2018 12; 120:1-11. PMID: 30149180.
    Citations: 1     Fields:    
  10. Hallett PJ, Huebecker M, Brekk OR, Moloney EB, Rocha EM, Priestman DA, Platt FM, Isacson O. Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. Neurobiol Aging. 2018 07; 67:189-200. PMID: 29735433.
    Citations: 1     Fields:    Translation:AnimalsCells
  11. Osborn TM, Beagan J, Isacson O. Increased motor neuron resilience by small molecule compounds that regulate IGF-II expression. Neurobiol Dis. 2018 02; 110:218-230. PMID: 29113829.
    Citations:    Fields:    
  12. Klemann CJHM, Martens GJM, Sharma M, Martens MB, Isacson O, Gasser T, Visser JE, Poelmans G. Integrated molecular landscape of Parkinson's disease. NPJ Parkinsons Dis. 2017; 3:14. PMID: 28649614.
    Citations: 4     
  13. Engelender S, Isacson O. The Threshold Theory for Parkinson's Disease. Trends Neurosci. 2017 01; 40(1):4-14. PMID: 27894611.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  14. Kordower JH, Vinuela A, Chu Y, Isacson O, Redmond DE. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512. PMID: 27418401.
    Citations: 1     Fields:    Translation:AnimalsCells
  15. Xiong N, Li N, Martin E, Yu J, Li J, Liu J, Lee DY, Isacson O, Vance J, Qing H, Wang T, Lin Z. hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics. 2016 07; 13(3):623-34. PMID: 27137201.
    Citations: 1     Fields:    Translation:HumansCells
  16. Wang X, Li N, Xiong N, You Q, Li J, Yu J, Qing H, Wang T, Cordell HJ, Isacson O, Vance JM, Martin ER, Zhao Y, Cohen BM, Buttner EA, Lin Z. Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. Mol Neurobiol. 2017 05; 54(4):2878-2888. PMID: 27021023.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  17. Jeon J, Kim W, Jang J, Isacson O, Seo H. Gene therapy by proteasome activator, PA28?, improves motor coordination and proteasome function in Huntington's disease YAC128 mice. Neuroscience. 2016 Jun 02; 324:20-8. PMID: 26944602.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  18. Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. a-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A. 2016 Feb 16; 113(7):1931-6. PMID: 26839413.
    Citations: 33     Fields:    Translation:HumansCells
  19. Korecka JA, Levy S, Isacson O. In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells. Mol Cell Neurosci. 2016 06; 73:3-12. PMID: 26691153.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  20. Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Glucocerebrosidase gene therapy prevents a-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015 Oct; 82:495-503. PMID: 26392287.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  21. Smith GA, Jansson J, Rocha EM, Osborn T, Hallett PJ, Isacson O. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. Mol Neurobiol. 2016 10; 53(8):5161-77. PMID: 26399642.
    Citations: 5     Fields:    Translation:HumansCells
  22. Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, McLean JR, Hayes MA, Beagan J, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain a-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Antioxid Redox Signal. 2015 Aug 20; 23(6):550-64. PMID: 26094487.
    Citations: 9     Fields:    Translation:AnimalsCells
  23. Isacson O. Lysosomes to combat Parkinson's disease. Nat Neurosci. 2015 Jun; 18(6):792-3. PMID: 26007211.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  24. Isacson O. Sorting the wheat from the chaff in dopamine neuron-based cell therapies. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4512-3. PMID: 25848026.
    Citations: 2     Fields:    Translation:AnimalsCells
  25. Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). PLoS One. 2015; 10(3):e0121072. PMID: 25815475.
    Citations: 11     Fields:    Translation:AnimalsCells
  26. Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 2015 Mar 05; 16(3):269-74. PMID: 25732245.
    Citations: 53     Fields:    Translation:HumansAnimalsCells
  27. Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett P, Isacson O. Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann Clin Transl Neurol. 2015 Apr; 2(4):433-8. PMID: 25909088.
    Citations: 22     
  28. Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep. 2014 Jun 26; 7(6):1755-61. PMID: 24910427.
    Citations: 32     Fields:    Translation:HumansCells
  29. McLean JR, Smith GA, Rocha EM, Osborn TM, Dib S, Hayes MA, Beagan JA, Brown TB, Lawson TF, Hallett PJ, Robertson J, Isacson O. ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. Exp Neurol. 2014 Nov; 261:217-29. PMID: 24907400.
    Citations: 2     Fields:    Translation:HumansCells
  30. McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ, Isacson O. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett. 2014 Jul 25; 576:73-8. PMID: 24882721.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  31. Zhang J, Saur T, Duke AN, Grant SG, Platt DM, Rowlett JK, Isacson O, Yao WD. Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95. J Neurogenet. 2014 Mar-Jun; 28(1-2):98-111. PMID: 24702501.
    Citations: 10     Fields:    Translation:AnimalsCells
  32. Smith GA, Rocha EM, McLean JR, Hayes MA, Izen SC, Isacson O, Hallett PJ. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet. 2014 Sep 01; 23(17):4510-27. PMID: 24728190.
    Citations: 19     Fields:    Translation:AnimalsCells
  33. Sundberg M, Isacson O. Advances in stem-cell--generated transplantation therapy for Parkinson's disease. Expert Opin Biol Ther. 2014 Apr; 14(4):437-53. PMID: 24437368.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  34. Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, Goldberg AL, Liu JL, Isacson O, Tofaris GK. Enhanced ubiquitin-dependent degradation by Nedd4 protects against a-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiol Dis. 2014 Apr; 64:79-87. PMID: 24388974.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  35. Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis. 2014 Feb; 62:381-6. PMID: 24148854.
    Citations: 50     Fields:    Translation:HumansCells
  36. Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013 Aug; 31(8):1548-62. PMID: 23666606.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  37. Olanow CW, Isacson O. Stem cells for Parkinson's disease: advancing science but protecting patients. Mov Disord. 2012 Oct; 27(12):1475-7. PMID: 23032987.
    Citations: 3     Fields:    Translation:HumansCells
  38. Wray S, Self M, Lewis PA, Taanman JW, Ryan NS, Mahoney CJ, Liang Y, Devine MJ, Sheerin UM, Houlden H, Morris HR, Healy D, Marti-Masso JF, Preza E, Barker S, Sutherland M, Corriveau RA, D'Andrea M, Schapira AH, Uitti RJ, Guttman M, Opala G, Jasinska-Myga B, Puschmann A, Nilsson C, Espay AJ, Slawek J, Gutmann L, Boeve BF, Boylan K, Stoessl AJ, Ross OA, Maragakis NJ, Van Gerpen J, Gerstenhaber M, Gwinn K, Dawson TM, Isacson O, Marder KS, Clark LN, Przedborski SE, Finkbeiner S, Rothstein JD, Wszolek ZK, Rossor MN, Hardy J. Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One. 2012; 7(8):e43099. PMID: 22952635.
    Citations: 19     Fields:    Translation:HumansCells
  39. Smith GA, Isacson O, Dunnett SB. The search for genetic mouse models of prodromal Parkinson's disease. Exp Neurol. 2012 Oct; 237(2):267-73. PMID: 22819262.
    Citations: 7     Fields:    Translation:HumansAnimals
  40. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Torres E, Clark L, Moskowitz C, Mazzulli J, Chen L, Volpicelli-Daley L, Romero N, Jiang H, Uitti RJ, Huang Z, Opala G, Scarffe LA, Dawson VL, Klein C, Feng J, Ross OA, Trojanowski JQ, Lee VM, Marder K, Surmeier DJ, Wszolek ZK, Przedborski S, Krainc D, Dawson TM, Isacson O. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med. 2012 Jul 04; 4(141):141ra90. PMID: 22764206.
    Citations: 132     Fields:    Translation:HumansCells
  41. Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O. a-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis. 2012 Aug; 47(2):258-67. PMID: 22549133.
    Citations: 20     Fields:    Translation:HumansAnimals
  42. Deleidi M, Isacson O. Viral and inflammatory triggers of neurodegenerative diseases. Sci Transl Med. 2012 Feb 15; 4(121):121ps3. PMID: 22344685.
    Citations: 10     Fields:    Translation:Humans
  43. Lindvall O, Barker RA, Brüstle O, Isacson O, Svendsen CN. Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell. 2012 Feb 03; 10(2):151-5. PMID: 22305565.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  44. Cooper O, Parmar M, Isacson O. Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy. Prog Brain Res. 2012; 200:265-76. PMID: 23195423.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  45. Cooper O, Hallett P, Isacson O. Using stem cells and iPS cells to discover new treatments for Parkinson's disease. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S14-6. PMID: 22166414.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  46. McLean JR, Hallett PJ, Cooper O, Stanley M, Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci. 2012 Feb; 49(2):230-9. PMID: 22155155.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  47. Deleidi M, Hargus G, Hallett P, Osborn T, Isacson O. Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. Stem Cells. 2011 Jul; 29(7):1052-63. PMID: 21608081.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  48. Deleidi M, Cooper O, Hargus G, Levy A, Isacson O. Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons. PLoS One. 2011; 6(5):e19926. PMID: 21655272.
    Citations: 11     Fields:    Translation:AnimalsCells
  49. Tsui A, Isacson O. Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease. J Neurol. 2011 Aug; 258(8):1393-405. PMID: 21544566.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  50. Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci. 2010 Dec 01; 30(48):16091-101. PMID: 21123556.
    Citations: 28     Fields:    Translation:Animals
  51. Isacson O, Mendez I. Being too inclusive about synuclein inclusions. Nat Med. 2010 Sep; 16(9):960-1; author reply 961. PMID: 20823871.
    Citations: 1     Fields:    Translation:HumansCells
  52. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, Osborn T, Jaenisch R, Isacson O. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A. 2010 Sep 07; 107(36):15921-6. PMID: 20798034.
    Citations: 141     Fields:    Translation:HumansAnimalsCells
  53. Seo H, Isacson O. The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome. J Neurochem. 2010 Sep; 114(6):1819-26. PMID: 20698932.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  54. Hedlund E, Karlsson M, Osborn T, Ludwig W, Isacson O. Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection. Brain. 2010 Aug; 133(Pt 8):2313-30. PMID: 20826431.
    Citations: 18     Fields:    Translation:AnimalsCells
  55. Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, Lee K, Levy A, Perez-Torres E, Yow A, Isacson O. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci. 2010 Nov; 45(3):258-66. PMID: 20603216.
    Citations: 69     Fields:    Translation:HumansAnimalsCells
  56. Chung CY, Licznerski P, Alavian KN, Simeone A, Lin Z, Martin E, Vance J, Isacson O. The transcription factor orthodenticle homeobox 2 influences axonal projections and vulnerability of midbrain dopaminergic neurons. Brain. 2010 Jul; 133(Pt 7):2022-31. PMID: 20573704.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  57. Lin Z, Zhao Y, Chung CY, Zhou Y, Xiong N, Glatt CE, Isacson O. High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J. 2010 Jul; 24(7):2191-200. PMID: 20181938.
    Citations: 9     Fields:    Translation:HumansCells
  58. Chung CY, Koprich JB, Hallett PJ, Isacson O. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22474-9. PMID: 20007772.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  59. Chung S, Leung A, Han BS, Chang MY, Moon JI, Kim CH, Hong S, Pruszak J, Isacson O, Kim KS. Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. Cell Stem Cell. 2009 Dec 04; 5(6):646-58. PMID: 19951692.
    Citations: 62     Fields:    Translation:AnimalsCells
  60. Pruszak J, Ludwig W, Blak A, Alavian K, Isacson O. CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells. 2009 Dec; 27(12):2928-40. PMID: 19725119.
    Citations: 69     Fields:    Translation:HumansAnimalsCells
  61. Pruszak J, Just L, Isacson O, Nikkhah G. Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains. Curr Protoc Stem Cell Biol. 2009 Dec; Chapter 2:Unit 2D.5. PMID: 19960452.
    Citations: 16     Fields:    Translation:AnimalsCells
  62. Isacson O. Cell therapy ahead for Parkinson's disease. Science. 2009 Nov 20; 326(5956):1060. PMID: 19965408.
    Citations: 3     Fields:    Translation:Humans
  63. Hallett PJ, Cooper O, Isacson O. No evidence for disease-like processes in fetal transplants. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):E104; author reply E105. PMID: 19805203.
    Citations: 1     Fields:    Translation:HumansCells
  64. Cooper O, Astradsson A, Hallett P, Robertson H, Mendez I, Isacson O. Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients. J Neurol. 2009 Aug; 256 Suppl 3:310-6. PMID: 19711122.
    Citations: 15     Fields:    Translation:HumansCells
  65. Astradsson A, Jenkins BG, Choi JK, Hallett PJ, Levesque MA, McDowell JS, Brownell AL, Spealman RD, Isacson O. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. Neurobiol Dis. 2009 Sep; 35(3):348-51. PMID: 19501164.
    Citations: 13     Fields:    Translation:Animals
  66. Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci. 2009 Mar 18; 29(11):3365-73. PMID: 19295143.
    Citations: 108     Fields:    Translation:HumansAnimalsCells
  67. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009 Mar 06; 136(5):964-77. PMID: 19269371.
    Citations: 519     Fields:    Translation:HumansCells
  68. Zhang J, Xu TX, Hallett PJ, Watanabe M, Grant SG, Isacson O, Yao WD. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J Neurosci. 2009 Mar 04; 29(9):2948-60. PMID: 19261890.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  69. Lin L, Lesnick TG, Maraganore DM, Isacson O. Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci. 2009 Mar; 32(3):142-9. PMID: 19162339.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  70. Pruszak J, Isacson O. Molecular and cellular determinants for generating ES-cell derived dopamine neurons for cell therapy. Adv Exp Med Biol. 2009; 651:112-23. PMID: 19731556.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  71. Hedlund E, Isacson O. ALS model glia can mediate toxicity to motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008 Dec 04; 3(6):575-6. PMID: 19041769.
    Citations: 7     Fields:    Translation:HumansCells
  72. Isacson O, Kordower JH. Future of cell and gene therapies for Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S122-38. PMID: 19127583.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  73. Vinuela A, Hallett PJ, Reske-Nielsen C, Patterson M, Sotnikova TD, Caron MG, Gainetdinov RR, Isacson O. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain. 2008 Dec; 131(Pt 12):3361-79. PMID: 18988638.
    Citations: 11     Fields:    Translation:AnimalsCells
  74. Sanchez-Pernaute R, Lee H, Patterson M, Reske-Nielsen C, Yoshizaki T, Sonntag KC, Studer L, Isacson O. Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease. Brain. 2008 Aug; 131(Pt 8):2127-39. PMID: 18669499.
    Citations: 21     Fields:    Translation:AnimalsCells
  75. Seo H, Kim W, Isacson O. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum Mol Genet. 2008 Oct 15; 17(20):3144-53. PMID: 18640989.
    Citations: 9     Fields:    Translation:HumansAnimals
  76. de Chevigny A, Cooper O, Vinuela A, Reske-Nielsen C, Lagace DC, Eisch AJ, Isacson O. Fate mapping and lineage analyses demonstrate the production of a large number of striatal neuroblasts after transforming growth factor alpha and noggin striatal infusions into the dopamine-depleted striatum. Stem Cells. 2008 Sep; 26(9):2349-60. PMID: 18556510.
    Citations: 17     Fields:    Translation:AnimalsCells
  77. Sanchez-Pernaute R, Wang JQ, Kuruppu D, Cao L, Tueckmantel W, Kozikowski A, Isacson O, Brownell AL. Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage. 2008 Aug 01; 42(1):248-51. PMID: 18501638.
    Citations: 14     Fields:    Translation:AnimalsCells
  78. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5856-61. PMID: 18391196.
    Citations: 381     Fields:    Translation:AnimalsCells
  79. Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med. 2008 May; 14(5):507-9. PMID: 18391961.
    Citations: 113     Fields:    Translation:HumansCells
  80. Hedlund E, Pruszak J, Lardaro T, Ludwig W, Viñuela A, Kim KS, Isacson O. Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells. 2008 Jun; 26(6):1526-36. PMID: 18388307.
    Citations: 44     Fields:    Translation:AnimalsCells
  81. Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis. 2008 Jun; 30(3):430-8. PMID: 18413287.
    Citations: 18     Fields:    Translation:Animals
  82. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008 Feb 27; 5:8. PMID: 18304357.
    Citations: 77     Fields:    Translation:AnimalsCells
  83. Astradsson A, Cooper O, Vinuela A, Isacson O. Recent advances in cell-based therapy for Parkinson disease. Neurosurg Focus. 2008; 24(3-4):E6. PMID: 18341409.
    Citations: 10     Fields:    Translation:HumansAnimals
  84. Hong S, Kang UJ, Isacson O, Kim KS. Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. J Neurochem. 2008 Jan; 104(2):316-24. PMID: 17944878.
    Citations: 24     Fields:    Translation:HumansCells
  85. Hedlund E, Hefferan MP, Marsala M, Isacson O. Cell therapy and stem cells in animal models of motor neuron disorders. Eur J Neurosci. 2007 Oct; 26(7):1721-37. PMID: 17897390.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  86. Inoue H, Lin L, Lee X, Shao Z, Mendes S, Snodgrass-Belt P, Sweigard H, Engber T, Pepinsky B, Yang L, Beal MF, Mi S, Isacson O. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A. 2007 Sep 04; 104(36):14430-5. PMID: 17726113.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  87. Redmond DE, Vinuela A, Kordower JH, Isacson O. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol Dis. 2008 Jan; 29(1):103-16. PMID: 17920901.
    Citations: 18     Fields:    Translation:Animals
  88. Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med. 2007 Aug; 4(8):e262. PMID: <